Creative Biolabs expands AI-driven synthesis platforms for drug discovery

Creative Biolabs said Sept. 9, 2026, that it has broadened its AI-driven chemical synthesis platforms to speed medicinal chemistry and reduce bottlenecks in drug discovery. The expanded workflow links molecular design, retrosynthesis, automated synthesis, and validation across small molecules, ADCs, and PROTACs.

Why it matters: - Creative Biolabs is targeting common drug discovery bottlenecks: compounds that are hard to synthesize, ADCs that are unstable or heterogeneous, and PROTACs that fail in linker or ternary-complex optimization. - The company’s integrated workflow is designed to shorten hit-to-lead timelines, reduce synthesis failures, and lower the attrition rate of early-stage candidates. - The platform aims to connect AI predictions directly to wet-lab synthesis, which can help biopharmaceutical teams move faster from concept to testable material.

What happened: - Creative Biolabs expanded its end-to-end AI-driven synthesis solutions to support modern medicinal chemistry and next-generation drug discovery. - The platform combines AI-based molecular design, synthetic feasibility assessment, automated chemical synthesis, and experimental validation in a single DMTA workflow. - The company said the framework supports tailored discovery pipelines for small molecules, antibody-drug conjugates, and targeted protein degraders. - Creative Biolabs said the platform is meant to bridge in silico predictions with automated wet-lab synthesis.

The details: - The company’s AI chemical synthesis and de novo design services are built to explore broad chemical space while embedding synthetic accessibility constraints into generative algorithms. - Multi-parametric lead optimization is used to balance potency, selectivity, ADMET profiles, and production costs. - Integrated retrosynthesis evaluates commercial building blocks and reaction pathways in silico to identify viable, high-yield synthetic routes. - Automated DMTA cycles connect virtual screening results to high-purity automated synthesis platforms for faster hit-to-lead transitions. - Creative Biolabs said the workflow is intended to reduce synthesis failures and speed early-stage development. - For ADC development, Creative Biolabs uses geometric graph neural networks and structural deep learning to predict conjugation sites, paratope integrity, and linker cleavage kinetics before bioconjugation. - Site-specific bioconjugation supports homogeneous DAR profiles through enzymatic, genetic, and Fc-affinity peptide-guided tagging. - Hydrophobicity masking uses hydrophilic branched PEG spacers and XTEN polypeptide linkers to reduce aggregation and support circulatory half-life. - Predictive DMPK and stability modeling is used to estimate plasma stability and help prevent premature payload release and off-target toxicity. - For PROTAC development, the company’s services simulate ternary complexes between the protein of interest, the E3 ligase, and the degrader. - Rational linker design evaluates linker geometries and attachment vectors to improve degradation selectivity. - The PROTAC synthesis workflow is designed to deliver bifunctional degraders with industry-standard high purity, typically greater than 95%, as verified by LC-MS and HPLC.

Between the lines: - Creative Biolabs is positioning AI as a practical manufacturing and decision-making layer, not just a modeling tool. - The broad platform approach suggests the company is trying to serve multiple discovery modalities with one integrated chemistry and validation stack. - The emphasis on synthetic feasibility reflects a wider industry shift away from designs that look good computationally but are difficult to make in the lab.

What's next: - Creative Biolabs is likely to continue pushing more discovery work into the DMTA loop as biopharma teams look for faster and more reliable candidate generation. - The company said the expanded platform is intended to help researchers obtain structurally validated materials ready for downstream evaluation. - More information is available in the company’s announcement.